Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 10/2008

01-10-2008 | Original Article

MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30 years after vaccination

Authors: S. T. Tang, M. Wang, K. Lamberth, M. Harndahl, M. H. Dziegiel, M. H. Claesson, S. Buus, O. Lund

Published in: Archives of Virology | Issue 10/2008

Login to get access

Abstract

It is many years since the general population has been vaccinated against smallpox virus. Here, we report that human leukocyte antigen (HLA) class I restricted T cell epitopes can be recognized more than 30 years after vaccination. Using bioinformatic methods, we predicted 177 potential cytotoxic T lymphocyte epitopes. Eight epitopes were confirmed to stimulate IFN-γ release by T cells in smallpox-vaccinated subjects. The epitopes were restricted by five supertypes (HLA-A1, -A2, -A24 -A26 and -B44). Significant T cell responses were detected against 8 of 45 peptides with an HLA class I affinity of K D less than or equal to 5 nM, whereas no T cell responses were detected against 60 peptides with an HLA affinity of K D more than 5 nM. All epitopes were fully conserved in seven variola, vaccinia and cowpox strains. Knowledge of the long-term response to smallpox vaccination may lead to a better understanding of poxvirus immunity and may aid in the development of new improved vaccines and diagnostic tools.
Literature
1.
Alcami A, Symons JA, Smith GL (2000) The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 74:11230–11239PubMedCrossRef
2.
Altschul SF (1991) Amino acid substitution matrices from an information theoretic perspective. J Mol Biol 219:555–565PubMedCrossRef
3.
Amara RR, Nigam P, Sharma S, Liu J, Bostik V (2004) Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78:3811–3816PubMedCrossRef
4.
Antoine G, Scheiflinger F, Dorner F, Falkner FG (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365–396PubMedCrossRef
5.
Bartlett N, Symons JA, Tscharke DC, Smith GL (2002) The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 83:1965–1976PubMed
6.
Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, Fast PE, Conlon C, Rowland-Jones S, McMichael AJ, Hanke T (2006) Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24:417–425PubMedCrossRef
7.
Chernos VI, Surgai VV (1980) Study of genome homology of some orthopoxviruses. Acta Virol 24:81–88PubMed
8.
Clark RH, Kenyon JC, Bartlett NW, Tscharke DC, Smith GL (2006) Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87:29–38PubMedCrossRef
9.
Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM (1995) Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270:15974–15978PubMedCrossRef
10.
Combadiere B, Boissonnas A, Carcelain G, Lefranc E, Samri A, Bricaire F, Debre P, Autran B (2004) Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 199:1585–1593PubMedCrossRef
11.
Condit RC, Xiang Y, Lewis JI (1996) Mutation of vaccinia virus gene G2R causes suppression of gene A18R ts mutants: implications for control of transcription. Virology 220:10–19PubMedCrossRef
12.
Cooray S, Bahar MW, Abrescia NG, McVey CE, Bartlett NW, Chen RA, Stuart DI, Grimes JM, Smith GL (2007) Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 88:1656–1666PubMedCrossRef
13.
Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R (2003) Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171:4969–4973PubMed
14.
Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu Y, Hirst S, Villarreal L, Felgner PL, Crotty S (2005) Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 79:11724–11733PubMedCrossRef
15.
DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, Zhang Z, Arvikar S, Latz E, Fitzgerald KA, Marshall WL (2004) Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 279:36570–36578PubMedCrossRef
16.
Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, Lemonnier FA, Rammensee HG, Busch DH, Bernhard H, Erfle V, Sutter G (2003) Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA 100:217–222PubMedCrossRef
17.
Gherardi MM, Esteban M (2005) Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol 86:2925–2936PubMedCrossRef
18.
Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E (1990) The complete DNA sequence of vaccinia virus. Virology 179(247–66):517–563
19.
Gubser C, Hue S, Kellam P, Smith GL (2004) Poxvirus genomes: a phylogenetic analysis. J Gen Virol 85:105–117PubMedCrossRef
20.
Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK (2003) Duration of antiviral immunity after smallpox vaccination. Nat Med 9:1131–1137PubMedCrossRef
21.
Huang J, Smirnov SV, Lewis-Antes A, Balan M, Li W, Tang S, Silke GV, Putz MM, Smith GL, Kotenko SV (2007) Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus. Proc Natl Acad Sci USA 104:9822–9827PubMedCrossRef
22.
Kennedy R, Poland GA (2007) T-Cell epitope discovery for variola and vaccinia viruses. Rev Med Virol 17:93–113PubMedCrossRef
23.
Kotwal GJ (1999) Virokines: mediators of virus-host interaction and future immunomodulators in medicine. Arch Immunol Ther Exp (Warsz) 47:135–138
24.
Larsen MV, Lundegaard C, Lamberth K, Buus S, Brunak S, Lund O, Nielsen M (2005) An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. Eur J Immunol 35:2295–2303PubMedCrossRef
25.
Lund O, Nielsen M, Kesmir C, Petersen AG, Lundegaard C, Worning P, Sylvester-Hvid C, Lamberth K, Roder G, Justesen S, Buus S, Brunak S (2004) Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 55:797–810PubMedCrossRef
26.
Mack TM (1972) Smallpox in Europe, 1950–1971. J Infect Dis 125:161–169PubMed
27.
Mathew A, Terajima M, West K, Green S, Rothman AL, Ennis FA, Kennedy JS (2005) Identification of murine poxvirus-specific CD8 + CTL epitopes with distinct functional profiles. J Immunol 174:2212–2219PubMed
28.
Moutaftsi M, Peters B, Pasquetto V, Tscharke DC, Sidney J, Bui HH, Grey H, Sette A (2006) A consensus epitope prediction approach identifies the breadth of murine T(CD8 +)-cell responses to vaccinia virus. Nat Biotechnol 24:817–819PubMedCrossRef
29.
Moutaftsi M, Bui HH, Peters B, Sidney J, Salek-Ardakani S, Oseroff C, Pasquetto V, Crotty S, Croft M, Lefkowitz EJ, Grey H, Sette A (2007) Vaccinia virus-specific CD4 + T cell responses target a set of antigens largely distinct from those targeted by CD8 + T cell responses. J Immunol 178:6814–6820PubMed
30.
Najarro P, Traktman P, Lewis JA (2001) Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol 75:3185–3196PubMedCrossRef
31.
Oseroff C, Kos F, Bui HH, Peters B, Pasquetto V, Glenn J, Palmore T, Sidney J, Tscharke DC, Bennink JR, Southwood S, Grey HM, Yewdell JW, Sette A (2005) HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci USA 102:13980–13985PubMedCrossRef
32.
Ostergaard Pedersen L, Nissen MH, Hansen NJ, Nielsen LL, Lauenmoller SL, Blicher T, Nansen A, Sylvester-Hvid C, Thromsen AR, Buus S (2001) Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds. Eur J Immunol 31:2986–2996PubMedCrossRef
33.
Ostrout ND, McHugh MM, Tisch DJ, Moormann AM, Brusic V, Kazura JW (2007) Long-term T cell memory to human leucocyte antigen-A2 supertype epitopes in humans vaccinated against smallpox. Clin Exp Immunol
34.
Panus JF, Smith CA, Ray CA, Smith TD, Patel DD, Pickup DJ (2002) Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue. Proc Natl Acad Sci USA 99:8348–8353PubMedCrossRef
35.
Pasquetto V, Bui HH, Giannino R, Banh C, Mirza F, Sidney J, Oseroff C, Tscharke DC, Irvine K, Bennink JR, Peters B, Southwood S, Cerundolo V, Grey H, Yewdell JW, Sette A (2005) HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol 175:5504–5515PubMed
36.
Putz MM, Midgley CM, Law M, Smith GL (2006) Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 12:1310–1315PubMedCrossRef
37.
Senkevich TG, Muravnik GL, Pozdnyakov SG, Chizhikov VE, Ryazankina OI, Shchelkunov SN, Koonin EV, Chernos VI (1993) Nucleotide sequence of XhoI O fragment of ectromelia virus DNA reveals significant differences from vaccinia virus. Virus Res 30:73–88PubMedCrossRef
38.
Senkevich TG, Moss B (1998) Domain structure, intracellular trafficking, and beta2-microglobulin binding of a major histocompatibility complex class I homolog encoded by molluscum contagiosum virus. Virology 250:397–407PubMedCrossRef
39.
Sette A, Sidney J (1999) Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50:201–212PubMedCrossRef
40.
Shchelkunov SN, Totmenin AV, Sandakhchiev LS (1996) Analysis of the nucleotide sequence of 23.8 kbp from the left terminus of the genome of variola major virus strain India–1967. Virus Res 40:169–183PubMedCrossRef
41.
Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA (2004) Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8 + T-cell peptide epitope of vaccinia and variola viruses. J Virol 78:7052–7060PubMedCrossRef
42.
Sylvester-Hvid C, Kristensen N, Blicher T, Ferre H, Lauemoller SL, Wolf XA, Lamberth K, Nissen MH, Pedersen LO, Buus S (2002) Establishment of a quantitative ELISA capable of determining peptide—MHC class I interaction. Tissue Antigens 59:251–258PubMedCrossRef
43.
Sylvester-Hvid C, Nielsen M, Lamberth K, Roder G, Justesen S, Lundegaard C, Worning P, Thomadsen H, Lund O, Brunak S, Buus S (2004) SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation. Tissue Antigens 63:395–400PubMedCrossRef
44.
Symons JA, Alcami A, Smith GL (1995) Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551–560PubMedCrossRef
45.
Terajima M, Cruz J, Raines G, Kilpatrick ED, Kennedy JS, Rothman AL, Ennis FA (2003) Quantitation of CD8 + T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 197:927–932PubMedCrossRef
46.
Terajima M, Cruz J, Leporati AM, Demkowicz WE Jr, Kennedy JS, Ennis FA (2006) Identification of vaccinia CD8 + T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Hum Immunol 67:512–520PubMedCrossRef
47.
Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, Haeryfar SM, Williams S, Sidney J, Sette A, Bennink JR, Yewdell JW (2005) Identification of poxvirus CD8 + T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201:95–104PubMedCrossRef
48.
Tscharke DC, Woo WP, Sakala IG, Sidney J, Sette A, Moss DJ, Bennink JR, Karupiah G, Yewdell JW (2006) Poxvirus CD8 + T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80:6318–6323PubMedCrossRef
49.
Wang M, Lamberth K, Harndahl M, Roder G, Stryhn A, Larsen MV, Nielsen M, Lundegaard C, Tang ST, Dziegiel MH, Rosenkvist J, Pedersen AE, Buus S, Claesson MH, Lund O (2007) CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 25:2823–2831PubMedCrossRef
50.
Yewdell JW, Bennink JR (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17:51–88PubMedCrossRef
Metadata
Title
MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30 years after vaccination
Authors
S. T. Tang
M. Wang
K. Lamberth
M. Harndahl
M. H. Dziegiel
M. H. Claesson
S. Buus
O. Lund
Publication date
01-10-2008
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 10/2008
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-008-0194-7

Other articles of this Issue 10/2008

Archives of Virology 10/2008 Go to the issue

Annotated Sequence Record

Six novel begomoviruses infecting tomato and associated weeds in Southeastern Brazil

Brief Report

Proposal for a fourth aquabirnavirus serogroup

Original Article

Pathogenicity of Chinese H5N1 highly pathogenic avian influenza viruses in pigeons

Original Article

Mutation spectra of the surface-protein-coding region of the HBV genome in HBV-vaccinated and non-vaccinated individuals in Hungary

Original Article

Biological and molecular characterization of a putative new sobemovirus infecting Imperata cylindrica and maize in Africa

Brief Report

Increased detection of influenza A H16 in the United States
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits